Please assess the completion status of the following clinical trial:

Trial Title: Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-infected~2. Age \>=18 years~3. Tuberculin skin test positive or negative~4. Laboratory:~   * Hemoglobin (Hgb) \>6.5 gm/dl;~  * Neutrophil count \>1,000 cells/mm3;~  * Platelets \>75,000/mm3;~  * AST (SGOT) \<122 U/L;~  * Creatinine \<1.5 mg/dl;~  * Beta HCG = negative~5. Karnofsky performance status \>=60~6. Signed informed consent~Exclusion Criteria:~1. History of TB in the last 3 years or current active TB~2. History of noncompliance to chronic therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous vs limited isoniazid (Type: EXPERIMENTAL): The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).

Based on this trial design, predict the completion outcome and termination type (if applicable).